PMID- 3744135
OWN - NLM
STAT- MEDLINE
DCOM- 19861016
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 16 Suppl 2
DP  - 1986
TI  - Pharmacokinetics of intravenously and subcutaneously administered Fragmin in 
      healthy volunteers.
PG  - 8-10
AB  - Studies in 8 healthy volunteers showed that the low molecular weight heparin 
      Fragmin KabiVitrum is eliminated according to first order kinetics without dose 
      dependency after intravenous injection of doses between 40 and 120 anti-Xa U/kg. 
      Fragmin remains in the circulation more than twice as long as unfractionated 
      heparin (UFH). Fragmin administered subcutaneously has a bioavailability which is 
      much greater than that of UFH. Fragmin administered subcutaneously twice a day 
      results in a significant anti-Xa activity and provides an alternative to 
      intravenous infusions.
FAU - Lockner, D
AU  - Lockner D
FAU - Bratt, G
AU  - Bratt G
FAU - Tornebohm, E
AU  - Tornebohm E
FAU - Aberg, W
AU  - Aberg W
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Biological Availability
MH  - Body Burden
MH  - Female
MH  - Heparin/administration & dosage/*metabolism/pharmacology
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Kinetics
MH  - Male
MH  - Molecular Weight
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
AID - 10.1159/000215349 [doi]
PST - ppublish
SO  - Haemostasis. 1986;16 Suppl 2:8-10. doi: 10.1159/000215349.